Hypokalemia induced by posaconazole
10.3760/cma.j.cn114015-20221121-01075
- VernacularTitle:泊沙康唑致低钾血症
- Author:
Rongrong WANG
1
;
Jiao LIU
1
;
Ping LENG
1
Author Information
1. 青岛大学附属医院药学部，青岛 266000
- Publication Type:Journal Article
- Keywords:
Hypokalemia;
Posaconazole;
Adverse drug reactions
- From:
Adverse Drug Reactions Journal
2023;25(12):766-768
- CountryChina
- Language:Chinese
-
Abstract:
A 61-year-old male patient with diffuse large B-cell lymphoma received BeEAM pre-treatment measures such as bendamustine, cytarabine, etoposide, and melphalan for autologous hematopoietic stem cell transplantation. Anti-infective treatments such as aciclovir, posaconazole, levofloxacin, biapenem, and vancomycin were administered successively. Before the pre-treatment of transplantation, the patient′s blood potassium was 4.1 mmol/L, and after 7 days of treatment with posaconazole and levofloxacin, the blood potassium was 3.4 mmol/L. Intravenous and oral potassium supplementation was administered. After 5 days of potassium supplement, the patient developed atrial fibrillation, with blood potassium level of 3.3 mmol/L. After continuing potassium supplement for 7 days, his blood potassium level remained 3.0 mmol/L. After excluding causes of other drugs, it was considered that hypokalemia might be related to posaconazole. The posaconazole was discontinued and switched to voriconazole; 3 days later, his blood potassium returned to 4.2 mmol/L. During a 3-month of follow-up, multiple examinations showed that the blood potassium levels were within the reference range.
